IMMUNE THROMBOCYTOPENIC PURPURA
Clinical trials for IMMUNE THROMBOCYTOPENIC PURPURA explained in plain language.
Never miss a new study
Get alerted when new IMMUNE THROMBOCYTOPENIC PURPURA trials appear
Sign up with your email to follow new studies for IMMUNE THROMBOCYTOPENIC PURPURA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a stronger rituximab dose prevent relapse in kids with ITP?
Disease control Recruiting nowThis study tests a stronger, more frequent dose of the drug rituximab in children and young adults (ages 1-21) with newly diagnosed immune thrombocytopenic purpura (ITP) who are at high risk for complications. The goal is to see if this approach can improve platelet counts and re…
Matched conditions: IMMUNE THROMBOCYTOPENIC PURPURA
Phase: PHASE1 • Sponsor: New York Medical College • Aim: Disease control
Last updated May 17, 2026 04:15 UTC
-
New drug hope for teens with rare bleeding disorder
Disease control Recruiting nowThis study tests an IV medicine called efgartigimod in teens aged 12 to 18 who have had immune thrombocytopenia (ITP) for over a year. ITP causes low platelet counts, leading to bruising and bleeding. The goal is to find the right dose and see if it safely raises platelet levels.…
Matched conditions: IMMUNE THROMBOCYTOPENIC PURPURA
Phase: PHASE2, PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 08, 2026 12:00 UTC